Ligand Pharmaceuticals Incorporated: all 58 studies

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• Safety and Immunogenicity of HIL-214 in Healthy Japanese InfantsCompletedNCT06007781Phase 1Results posted
• Serologic Assay Validation and Proficiency Testing of HIL-214 in AdultsCompletedNCT05972733Phase 2Results posted
• Safety and Immunogenicity of HIL-214 With Routine Pediatric VaccinesCompletedNCT05836012Phase 2/3Results posted
• Efficacy and Safety of Two Doses of HIL-214 in ChildrenTerminatedNCT05281094Phase 2/3Results posted
• A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With HypertensionCompletedNCT00635232Phase 2Results posted
• A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat HypertensionCompletedNCT00522925Phase 2Results posted
• A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid TumorsTerminatedNCT05576077Phase 1
• Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate CancerTerminatedNCT05369000Phase 1
• A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene AlterationsTerminatedNCT05242822Phase 1
• Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AMLTerminatedNCT04887259Phase 1
• Comparison of Captisol-Enabled™ Iohexol and Omnipaque™ in Patients With Impaired Renal Function Undergoing Coronary AngiographyWithdrawnNCT04627831Phase 2
• Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid TumorsTerminatedNCT04301011Phase 1
• MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell CarcinomaWithdrawnNCT03773744Phase 1
• This is a Trial of MG1-E6E7 With Ad-E6E7 and Atezolizumab in Patients With HPV Associated CancersTerminatedNCT03618953Phase 1
• Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer PatientsCompletedNCT02879760Phase 1/2
• A Study of LGD-6972 in Patients With Type 2 Diabetes MellitusCompletedNCT02851849Phase 2
• An Open-Label Study of XOMA 358 in Patients With Hypoglycemia After Gastric Bypass SurgeryCompletedNCT02772718Phase 2
• A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution FormulationCompletedNCT02672839Phase 1
• A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital HyperinsulinismCompletedNCT02604485Phase 2
• An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma GangrenosumTerminatedNCT02326740Phase 3
• A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma GangrenosumTerminatedNCT02318914Phase 3
• An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma GangrenosumTerminatedNCT02315417Phase 3
• Open-label Safety Extension Study of Gevokizumab in Erosive Osteoarthritis of the HandCompletedNCT02293564Not applicable
• Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease UveitisTerminatedNCT02258867Phase 3
• An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety DataTerminatedNCT02258854Phase 3
• Safety and Tolerability Study of Oral LGD-6972 for Type 2 Diabetes MellitusCompletedNCT02250222Phase 1
• The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear DiseaseCompletedNCT01950312Phase 2
• Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes MellitusCompletedNCT01919684Phase 1
• Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma GangrenosumCompletedNCT01882504Phase 2
• Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the HandCompletedNCT01882491Phase 2
• Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic TreatmentTerminatedNCT01747538Phase 3
• Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious UveitisTerminatedNCT01684345Phase 3
• Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the HandCompletedNCT01683396Phase 2
• Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne VulgarisCompletedNCT01498874Phase 2
• Study of the Safety and Biologic Activity of XOMA 052 in Subjects With Type 2 Diabetes MellitusCompletedNCT01144975Phase 2
• Safety and Efficacy of XOMA 052 in Subjects With Type 2 Diabetes Mellitus on Stable Metformin MonotherapyCompletedNCT01066715Phase 2
• Study of the Effects of XOMA 052 on Insulin Production in Subjects With Well Controlled Type 1 DiabetesCompletedNCT00998699Phase 2
• Compare Captisol-Enabled (CE) Budesonide + Azelastine Nasal Solution and Rhinocort Aqua + Astelin in an Environmental Exposure Chamber (EEC) Study of Allergic RhinitisCompletedNCT00940953Phase 2
• Compare CE-Budesonide Nasal Solution & Rhinocort Aqua in an EEC Study of ARCompletedNCT00938613Phase 2
• Study of MB07811 in Subjects With HypercholesterolemiaWithdrawnNCT00879112Phase 2
• Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Active, Stable, Moderate to Severe Rheumatoid ArthritisSuspendedNCT00777816Phase 2
• The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine EvaluationCompletedNCT00674453Phase 2
• The Effects of Aplindore on the Treatment of Signs and Symptoms of Restless Legs SyndromeCompletedNCT00626418Phase 2
• The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's DiseaseCompletedNCT00623324Phase 2
• Single-dose, Dose-escalation Study of Safety, PK, and Preliminary Efficacy of XOMA 052 in Type 2 Diabetes MellitusCompletedNCT00541983Phase 1
• Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Type 2 Diabetes MellitusCompletedNCT00513214Phase 1/2
• Safety, Tolerability, and Efficacy Study of MB07803 Administered to Patients With Type 2 Diabetes MellitusCompletedNCT00458016Phase 2
• Study of Opebacan in Patients Undergoing Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)TerminatedNCT00454155Phase 1/2
• Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone LossCompletedNCT00163137Phase 3
• Dose Response Study of Lasofoxifene in Postmenopausal Women With Osteoporosis - Japanese Asian Dose EvaluationCompletedNCT00143273Phase 2
• Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL)CompletedNCT00141323Phase 3
• Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular CarcinomaCompletedNCT00073736Phase 1/2
• Phase I Study of a Monoclonal Antibody for Treatment of Advanced AdenocarcinomasCompletedNCT00051675Phase 1
• Safety, Efficacy and Pharmacokinetics of an Antibody for Psoriatic ArthritisCompletedNCT00051662Phase 1
• Safety and Efficacy of a Monoclonal Antibody for Treatment of Rheumatoid Arthritis.CompletedNCT00034203Phase 2
• Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell LymphomaCompletedNCT00006345Phase 2
• Bexarotene in Treating Patients With Metastatic Breast CancerCompletedNCT00003752Phase 2
• A Study of Targretin Capsules in Patients With AIDS-Related Kaposi's SarcomaCompletedNCT00002212Phase 2

← Ligand Pharmaceuticals Incorporated overview and focus areas